Work

Supplementary Table S5 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer

Year: 2026

Type: supplementary-materials

Abstract: Most common AEs (in ≥5% of patients) possibly related to oleclumab

DOI: 10.1158/1078-0432.33253289

Authors: Peter Schmid, Cynthia X. Ma, Yeon Hee Park, Simon Lord, Anne Armstrong, Seock-Ah Im, Shin-Cheh Chen, Ricardo Fernandes, Jacek Jassem, Piotr J. Wysocki, Yen-Shen Lu, Hwei-Chung Wang, Wei-Pang Chung, Purnima Rao-Melacini, Katrin Heider, Ross Stewart, Petra Vuković, Kyung Hae Jung

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7203467188

Cites:

Cited by:

Related to: